## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the abstract; no full text, figures, tables, or supplementary materials were provided
- **Shared manuscript claim summary** The authors propose that rifampicin, a known PXR activator, destabilizes the TIP60-PXR complex through structural disruption, leading to impaired wound-induced cell migration. This conclusion is supported by computational docking, molecular dynamics simulations, MM-PBSA binding free energy calculations, live-cell imaging, and coimmunoprecipitation assays across multiple cell lines.
- **Visible evidence base** Abstract text only; no numerical data, statistical details, figure legends, or methodological specifics are available
- **Missing materials affecting confidence** Full manuscript, all figures and tables, computational parameters, simulation lengths, cell line identities, statistical analysis details, and raw data

## Reviewer
- **Overall assessment** The abstract presents a potentially interesting mechanistic hypothesis linking ligand-induced conformational changes in PXR to disruption of a coregulator complex and downstream functional consequences. However, the evidence as summarized is insufficient to establish the central claims. Key quantitative data, statistical rigor, and methodological details are absent. The computational findings are described qualitatively, and the cellular validation lacks specific metrics. The claim that rifampicin "uniquely" destabilizes the complex is not supported by comparative data presented in the abstract. The significance statement overreaches relative to the evidence shown.
- **Who would be interested in the results, and why** Researchers in nuclear receptor biology, drug safety pharmacology, and tissue repair biology would find this work relevant. Those studying PXR-mediated non-genomic effects, coregulator interactions, or ligand-biased signaling may be particularly interested. The potential clinical implication for rifampicin's effects on wound healing could interest clinicians using this drug long-term.
- **Major strengths** The study combines computational and experimental approaches, which is commendable. The focus on ligand-dependent modulation of coregulator interactions rather than classical transcriptional activation is a useful conceptual angle. The use of multiple cell lines to correlate effects with PXR expression levels is a reasonable validation strategy.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
  - R1-M4
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3, R1-M4
- **Assessment against Nature-style criteria** Originality: moderate. The concept of ligand-induced disruption of a PXR-coregulator complex is not entirely novel, as ligand-dependent coregulator exchange is well established in nuclear receptor biology. Scientific importance: potentially significant for drug safety, but the clinical relevance is not established from the abstract. Interdisciplinary readership: the work could appeal to structural biologists, pharmacologists, and cell biologists, but the abstract does not provide enough depth for any single discipline. Technical soundness: cannot be adequately assessed from the abstract alone; computational methods lack detail and experimental validation lacks quantitative reporting. Readability for nonspecialists: the abstract is generally clear but uses specialized terminology without sufficient context.
- **Recommendation posture** Currently not established from the provided evidence. The abstract suggests a plausible mechanism, but the absence of quantitative data, statistical analysis, and methodological detail prevents assessment of whether the claims are supported.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence sufficiency
- **Claim pointer** "rifampicin showed a significantly higher binding energy when docked with the complex, suggesting destabilization"
- **Evidence pointer** Abstract, computational docking section; location not provided
- **Concern** The abstract states that rifampicin showed a "significantly higher binding energy" but provides no numerical values, no comparison to other ligands beyond a qualitative statement, and no statistical test. The term "significantly" is used without supporting data. Additionally, the relationship between higher binding energy and destabilization is not explained mechanistically.
- **Why it matters** Without quantitative docking scores and appropriate statistical comparisons, the claim that rifampicin uniquely destabilizes the complex cannot be evaluated. Higher binding energy could reflect stronger binding rather than destabilization, and the interpretation depends on the sign convention used, which is not stated.
- **Resolution test** Provide docking energy values for all tested ligands in both PXR alone and the TIP60-PXR complex, with standard deviations and statistical comparisons. Clarify the sign convention and explain why higher binding energy in the complex context indicates destabilization rather than stabilization.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Methodological transparency
- **Claim pointer** "Molecular dynamics simulations revealed that rifampicin disrupts key interface residues, with significant root mean square deviation fluctuations and a failure to stabilize the complex"
- **Evidence pointer** Abstract, molecular dynamics section; location not provided
- **Concern** No simulation parameters are provided, including force field, simulation length, number of replicates, temperature, or solvent conditions. The claim of "significant" RMSD fluctuations is not quantified. The phrase "failure to stabilize the complex" is vague and does not specify which metric was used to assess stabilization.
- **Why it matters** Molecular dynamics results are highly sensitive to simulation setup. Without these details, the reproducibility and validity of the findings cannot be assessed. The qualitative description of RMSD fluctuations does not constitute evidence of disruption.
- **Resolution test** Provide full simulation parameters, including software, force field, water model, ion concentration, simulation time, and replicate numbers. Report RMSD and RMSF values with error bars for both apo and rifampicin-bound states. Define the stabilization criterion and show comparative data for a non-disrupting ligand.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Quantitative evidence
- **Claim pointer** "Rifampicin treatment drastically reduced the intracellular colocalization and physical interaction between TIP60 and PXR, thereby significantly compromising their ability to support wound-induced cell migration"
- **Evidence pointer** Abstract, live-cell imaging and coimmunoprecipitation sections; location not provided
- **Concern** The abstract reports "drastically reduced" colocalization and interaction without any quantitative metrics. No correlation coefficients, immunoprecipitation band intensities, or statistical values are provided. The wound migration assay results are described only as "significantly compromising" without migration rates, wound closure percentages, or time-course data.
- **Why it matters** The central functional claim depends on these cellular experiments. Without quantitative data and statistical analysis, the magnitude and reproducibility of the effect cannot be evaluated. The correlation with PXR expression levels across cell lines is mentioned but not shown.
- **Resolution test** Provide colocalization coefficients with standard errors, immunoprecipitation quantification normalized to input controls, wound closure percentages over time, and statistical comparisons between treated and untreated conditions for each cell line.

- **Concern ID** R1-M4
- **Severity** Major
- **Blocking** Yes
- **Axis** Claim scope
- **Claim pointer** "Our findings establish a direct mechanistic link between ligand-induced structural changes in PXR and the functional impairment of the TIP60-PXR complex"
- **Evidence pointer** Abstract, conclusion section; location not provided
- **Concern** The abstract claims a "direct mechanistic link" but the evidence presented is correlative. Computational predictions are connected to cellular observations, but no causal experiment is described, such as a mutant PXR that cannot bind rifampicin or a rescue experiment. The phrase "direct mechanistic link" overstates what the described experiments can establish.
- **Why it matters** The central scientific contribution of the paper depends on establishing causality. Without a loss-of-function or rescue experiment, alternative explanations, such as off-target effects of rifampicin or indirect transcriptional consequences, cannot be excluded.
- **Resolution test** Include experiments with a rifampicin-binding-deficient PXR mutant or a TIP60 mutant that cannot interact with PXR, showing that the effect on migration is dependent on the specific interaction. Alternatively, provide evidence that the computational predictions are validated by structure-function studies.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Terminology precision
- **Affected element** "significantly higher binding energy"
- **Evidence pointer** Abstract, docking section; location not provided
- **Issue** The term "significantly" is used without statistical context. In computational docking, significance is not typically assessed by statistical tests, and the term may mislead readers.
- **Required correction** Replace "significantly" with the actual numerical difference and state whether the difference exceeds a predefined threshold.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Comparative evidence
- **Affected element** "among them, rifampicin... emerged as a notable disruptor"
- **Evidence pointer** Abstract, ligand screening section; location not provided
- **Issue** The abstract does not state how many ligands were tested or how the others performed. The claim that rifampicin is "notable" requires context on the range of effects observed across the ligand panel.
- **Required correction** State the number of ligands tested and provide a summary of the range of binding energies or stability metrics observed, with rifampicin positioned within that range.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Clinical relevance
- **Affected element** "offers new insights for designing targeted therapeutics aimed at enhancing tissue repair"
- **Evidence pointer** Abstract, significance statement; location not provided
- **Issue** The therapeutic implication is stated without any discussion of whether rifampicin concentrations used in the study are clinically relevant or whether the effect is observed at therapeutic doses.
- **Required correction** Add a statement addressing the concentration range used relative to clinically achievable plasma levels, or temper the therapeutic claim accordingly.

## Risk / unsupported claims
- The claim that rifampicin "uniquely" destabilizes the TIP60-PXR complex is unsupported because comparative data for other ligands are not presented in the abstract.
- The claim of a "direct mechanistic link" is unsupported because no causal experiments are described.
- The claim that the study "provides a critical platform" for therapeutic design is overstated given the preliminary nature of the evidence.
- The significance statement's implication for drug safety is not supported by any data on adverse outcomes in vivo.
- The correlation between PXR expression levels and the observed effects across cell lines is mentioned but not demonstrated with data.